FHTX
FHTX
NASDAQ · Biotechnology

Foghorn Therapeutics Inc

$2.03
-0.05 (-2.40%)
As of Nov 7, 2:12 AM ET ·
Financial Highlights (FY 2026)
Revenue
26.85M
Net Income
-64,524,193
Gross Margin
—
Profit Margin
-240.3%
Rev Growth
+17.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 26.85M 22.92M 271.86M 230.16M
Gross Profit — — 96.87M 82.01M
Operating Income -75,040,454 -57,654,437 13.80M 11.27M
Net Income -64,524,193 -49,574,674 13.33M 11.49M
Gross Margin — — 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Rev Growth +17.1% +17.1% -6.6% +8.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 139.92M 178.86M
Total Equity — — 241.00M 245.51M
D/E Ratio — — 0.58 0.73
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -72,144,557 -58,508,903 20.13M 16.16M
Free Cash Flow — — 11.27M 12.60M